Utility:
| The 2019 EULAR/ACR classification criteria for SLE improve specificity as compared to the 2012 criteria (93.4% vs. 83.7%) while sensitivity is maintained (96.1 % vs. 96.7%, respectively). The largest change in the update is the requirement of at least one positive ANA at ? 1:80 by immunofluorescence on HEp-2 cells or equivalent solid-phase screening assays as an entry criteria for SLE. Following the positive ANA the subsequent weighted criteria continue to include three classes of immunologic markers including SLE-specific antibodies (anti-dsDNA or Sm antibodies), antiphospholipid antibodies (Anticardiolipin IgA, IgG, or IgM at medium or high titer, positive anti-B2GP1 IgA, IgG, or IgM, or positive lupus anticoagulant), or complement proteins (C3 and C4). The 2019 criteria defines dsDNA positivity as detected by an immunoassays with a demonstrated specificity of ?90% for SLE against relevant disease controls |